Short-term teriparatide treatment does not affect NT-proBNP, a marker of cardiac disease
Research output: Contribution to journal › Journal article › Research › peer-review
Teriparatide (Parathyroid hormone (PTH) 1-34) has been shown to increase bone mineral density (BMD) and reduce the risk of vertebral fractures when given intermittently. In contrast primary hyperparathyroidism (PHPT) is associated with increased bone loss. Moreover an increased occurrence of cardiovascular disease (CVD) is seen in PHPT patients. The N-terminal fragment of the pro-peptide of Brain Natriuretic peptide (NT-proBNP), a risk marker of CVD, has been shown to be elevated in PHPT patients, indicating that continuously high concentrations of PTH affect the heart. Therefore the aim of this study was to investigate whether teriparatide treatment is associated with changes in plasma NT-proBNP.
|Journal||Scandinavian Journal of Clinical & Laboratory Investigation|
|Number of pages||5|
|Publication status||Published - 2012|